Climb Bio Secures $110M in Private Placement Financing

Climb Bio (NASDAQ:CLYM) has entered into a private placement agreement to raise approximately $110 million through the sale of shares and pre-funded warrants. The financing is expected to strengthen its financial position as it advances its therapeutic pipeline for immune-mediated diseases.

By Maham Fatima Tue, May 5, 2026 at 8:05 PM GMT+3 2 min read · Yahoo Finance · May 5, 2026, 17:05 UTC

Climb Bio Secures $110M in Private Placement Financing

Topics: biotech financing stock_issuance

Read the full article at Yahoo Finance

More World news

Major Corporate Earnings Scheduled for Release After Thursday Market Close Seeking Alpha · November 12, 2026, 15:00 UTC
U.S. Existing Home Sales Decline More Than Expected in October Seeking Alpha · November 12, 2026, 15:03 UTC
Ascendis Pharma Reports Strong Q3 2026 Results Driven by Yorvipath Growth Motley Fool · November 12, 2026, 15:09 UTC
Pomerantz Law Firm Investigates Omeros Corporation Following Regulatory Setbacks PR Newswire · November 12, 2026, 15:10 UTC
Pomerantz Law Firm Investigates Innodata Inc. Following Mass Layoffs and Stock Price Drop PR Newswire · November 12, 2026, 15:10 UTC
Nightview Fund Rebalances Portfolio with Exits from Autodesk and Las Vegas Sands Seeking Alpha · November 12, 2026, 15:05 UTC
Nvidia Traders Speculate on Successors Following Jensen Huang's Resignation CNBC · November 12, 2026, 15:06 UTC
Pomerantz Law Firm Investigates Cumberland Pharmaceuticals Following Clinical Trial Results and Stock Decline PR Newswire · November 12, 2026, 15:05 UTC
Bybit Launches Fiat-to-Crypto Rewards Campaign with 80,000 USDT Weekly Prize Pool PR Newswire · November 12, 2026, 15:06 UTC
U.S. Existing Home Sales Decline More Than Expected in October Seeking Alpha · November 12, 2026, 15:03 UTC